191 related articles for article (PubMed ID: 21624387)
1. Stimulus control by 5-methoxy-N,N-dimethyltryptamine in wild-type and CYP2D6-humanized mice.
Winter JC; Amorosi DJ; Rice KC; Cheng K; Yu AM
Pharmacol Biochem Behav; 2011 Sep; 99(3):311-5. PubMed ID: 21624387
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic interactions between monoamine oxidase A inhibitor harmaline and 5-methoxy-N,N-dimethyltryptamine, and the impact of CYP2D6 status.
Jiang XL; Shen HW; Mager DE; Yu AM
Drug Metab Dispos; 2013 May; 41(5):975-86. PubMed ID: 23393220
[TBL] [Abstract][Full Text] [Related]
3. Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics.
Shen HW; Wu C; Jiang XL; Yu AM
Biochem Pharmacol; 2010 Jul; 80(1):122-8. PubMed ID: 20206139
[TBL] [Abstract][Full Text] [Related]
4. Potentiation of 5-methoxy-N,N-dimethyltryptamine-induced hyperthermia by harmaline and the involvement of activation of 5-HT1A and 5-HT2A receptors.
Jiang XL; Shen HW; Yu AM
Neuropharmacology; 2015 Feb; 89():342-51. PubMed ID: 25446678
[TBL] [Abstract][Full Text] [Related]
5. Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions.
Shen HW; Jiang XL; Winter JC; Yu AM
Curr Drug Metab; 2010 Oct; 11(8):659-66. PubMed ID: 20942780
[TBL] [Abstract][Full Text] [Related]
6. Nonlinear pharmacokinetics of 5-methoxy-N,N-dimethyltryptamine in mice.
Shen HW; Jiang XL; Yu AM
Drug Metab Dispos; 2011 Jul; 39(7):1227-34. PubMed ID: 21464174
[TBL] [Abstract][Full Text] [Related]
7. Modification of 5-methoxy-N,N-dimethyltryptamine-induced hyperactivity by monoamine oxidase A inhibitor harmaline in mice and the underlying serotonergic mechanisms.
Jiang XL; Shen HW; Yu AM
Pharmacol Rep; 2016 Jun; 68(3):608-15. PubMed ID: 26977821
[TBL] [Abstract][Full Text] [Related]
8. Modification of the effects of 5-methoxy-N,N-dimethyltryptamine on exploratory behavior in rats by monoamine oxidase inhibitors.
Halberstadt AL; Buell MR; Masten VL; Risbrough VB; Geyer MA
Psychopharmacology (Berl); 2008 Nov; 201(1):55-66. PubMed ID: 18604652
[TBL] [Abstract][Full Text] [Related]
9. The paradox of 5-methoxy-N,N-dimethyltryptamine: an indoleamine hallucinogen that induces stimulus control via 5-HT1A receptors.
Winter JC; Filipink RA; Timineri D; Helsley SE; Rabin RA
Pharmacol Biochem Behav; 2000 Jan; 65(1):75-82. PubMed ID: 10638639
[TBL] [Abstract][Full Text] [Related]
10. "In vivo biosynthesis of N,N-dimethyltryptamine, 5-MeO-N,N-dimethyltryptamine, and bufotenine in E.coli".
Friedberg LM; Sen AK; Nguyen Q; Tonucci GP; Hellwarth EB; Gibbons WJ; Jones JA
Metab Eng; 2023 Jul; 78():61-71. PubMed ID: 37230161
[TBL] [Abstract][Full Text] [Related]
11. Behavioral and pharmacokinetic interactions between monoamine oxidase inhibitors and the hallucinogen 5-methoxy-N,N-dimethyltryptamine.
Halberstadt AL
Pharmacol Biochem Behav; 2016 Apr; 143():1-10. PubMed ID: 26780349
[TBL] [Abstract][Full Text] [Related]
12. The serotonergic hallucinogen 5-methoxy-N,N-dimethyltryptamine disrupts cortical activity in a regionally-selective manner via 5-HT(1A) and 5-HT(2A) receptors.
Riga MS; Bortolozzi A; Campa L; Artigas F; Celada P
Neuropharmacology; 2016 Feb; 101():370-8. PubMed ID: 26477571
[TBL] [Abstract][Full Text] [Related]
13. Development of a LC-MS/MS method to analyze 5-methoxy-N,N-dimethyltryptamine and bufotenine, and application to pharmacokinetic study.
Shen HW; Jiang XL; Yu AM
Bioanalysis; 2009 Apr; 1(1):87-95. PubMed ID: 20523750
[TBL] [Abstract][Full Text] [Related]
14. Behavioral effects of α,α,β,β-tetradeutero-5-MeO-DMT in rats: comparison with 5-MeO-DMT administered in combination with a monoamine oxidase inhibitor.
Halberstadt AL; Nichols DE; Geyer MA
Psychopharmacology (Berl); 2012 Jun; 221(4):709-18. PubMed ID: 22222861
[TBL] [Abstract][Full Text] [Related]
15. Pharmepéna-Psychonautics: Human intranasal, sublingual and oral pharmacology of 5-methoxy-N,N-dimethyl-tryptamine.
Ott J
J Psychoactive Drugs; 2001; 33(4):403-7. PubMed ID: 11824699
[TBL] [Abstract][Full Text] [Related]
16. Development of a mechanism-based pharmacokinetic/pharmacodynamic model to characterize the thermoregulatory effects of serotonergic drugs in mice.
Jiang XL; Shen HW; Mager DE; Schmidt S; Yu AM
Acta Pharm Sin B; 2016 Sep; 6(5):492-503. PubMed ID: 27709018
[TBL] [Abstract][Full Text] [Related]
17. The clinical pharmacology and potential therapeutic applications of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT).
Reckweg JT; Uthaug MV; Szabo A; Davis AK; Lancelotta R; Mason NL; Ramaekers JG
J Neurochem; 2022 Jul; 162(1):128-146. PubMed ID: 35149998
[TBL] [Abstract][Full Text] [Related]
18. Intrathecal 5-methoxy-N,N-dimethyltryptamine in mice modulates 5-HT1 and 5-HT3 receptors.
Alhaider AA; Hamon M; Wilcox GL
Eur J Pharmacol; 1993 Nov; 249(2):151-60. PubMed ID: 7507056
[TBL] [Abstract][Full Text] [Related]
19. The epidemiology of 5-methoxy- N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption.
Davis AK; Barsuglia JP; Lancelotta R; Grant RM; Renn E
J Psychopharmacol; 2018 Jul; 32(7):779-792. PubMed ID: 29708042
[TBL] [Abstract][Full Text] [Related]
20. 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety.
Davis AK; So S; Lancelotta R; Barsuglia JP; Griffiths RR
Am J Drug Alcohol Abuse; 2019; 45(2):161-169. PubMed ID: 30822141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
